But achieving this goal will be a challenge, as it will add some USD 2 billion a year to the bill to fight the 32-year AIDS epidemic, they acknowledged.
"Treating people with HIV earlier ... Can both keep them healthy and lowers the amount of virus in the blood, which reduces the risk of passing it to someone else," the World Health Organisation (WHO) said in new recommendations for combating the HIV/AIDS pandemic.
Around 34 million people worldwide were living with the human immunodeficiency virus (HIV) in 2011, nearly 70% of them in sub-Saharan Africa, according to WHO statistics.
The UN agency's previous treatment guidelines, set down in 2010, called for drug initiation when the tally of CD4 cells -- the key immune cells targeted by HIV -- reached 350 cells or less per microlitre of blood.
Under this benchmark, 16.7 million people in low and middle-income countries were medically eligible last year to receive the drug "cocktail", which rolls back infection although it does not cure it.
Despite years of fund-raising and efforts to build medical infrastructure in poor countries, only 9.7 million of the 16.7 million currently get the treatment.
Today, WHO said that, after weighing evidence for drug efficacy, benefits for the immune system and potential side effects, it recommended raising the CD4 threshold to 500 cells per microlitre of blood.
That means treatment should start at a much earlier stage of infection.
This, along with the recommendation to treat all infected pregnant women and children under five - as well as other vulnerable groups, regardless of their cell-count - brings the number of patients who are advised to take these drugs to some 26 million, the WHO said.
"These guidelines represent another leap ahead in a trend of ever-higher goals and ever-greater achievements," WHO chief Margaret Chan said.
"With nearly 10 million people now on antiretroviral therapy, we see that such prospects - unthinkable just a few years ago - can now fuel the momentum needed to push the HIV epidemic into irreversible decline," she added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)